1.92 USD
-0.09 (-4.48%)
1.89 USD
-0.03 (-1.56%)
Overall OGI gets a fundamental rating of 3 out of 10. We evaluated OGI against 192 industry peers in the Pharmaceuticals industry. OGI has a bad profitability rating. Also its financial health evaluation is rather negative. OGI is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
OGI had negative earnings in the past year.
In the past year OGI has reported a negative cash flow from operations.
OGI had negative earnings in each of the past 5 years.
In the past 5 years OGI reported 4 times negative operating cash flow.
1.2 Ratios
With a decent Return On Assets value of -4.40%, OGI is doing good in the industry, outperforming 72.92% of the companies in the same industry.
Looking at the Return On Equity, with a value of -7.09%, OGI is in the better half of the industry, outperforming 76.04% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.4% | ||
| ROE | -7.09% | ||
| ROIC | N/A |
ROA(3y)-32.94%
ROA(5y)-24.98%
ROE(3y)-37.82%
ROE(5y)-28.71%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
OGI has a Gross Margin (6.64%) which is in line with its industry peers.
OGI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 6.64% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
OGI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, OGI has more shares outstanding
OGI has more shares outstanding than it did 5 years ago.
The debt/assets ratio for OGI is higher compared to a year ago.
2.2 Solvency
OGI has an Altman-Z score of -0.14. This is a bad value and indicates that OGI is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.14, OGI is in line with its industry, outperforming 45.31% of the companies in the same industry.
A Debt/Equity ratio of 0.22 indicates that OGI is not too dependend on debt financing.
The Debt to Equity ratio of OGI (0.22) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.14 |
ROIC/WACCN/A
WACC8.35%
2.3 Liquidity
A Current Ratio of 2.26 indicates that OGI has no problem at all paying its short term obligations.
OGI has a Current ratio (2.26) which is in line with its industry peers.
OGI has a Quick Ratio of 1.28. This is a normal value and indicates that OGI is financially healthy and should not expect problems in meeting its short term obligations.
OGI has a worse Quick ratio (1.28) than 69.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.26 | ||
| Quick Ratio | 1.28 |
3. Growth
3.1 Past
OGI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 60.25%, which is quite impressive.
Looking at the last year, OGI shows a very strong growth in Revenue. The Revenue has grown by 62.15%.
The Revenue has been growing by 24.46% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)60.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-258.7%
Revenue 1Y (TTM)62.15%
Revenue growth 3Y21.14%
Revenue growth 5Y24.46%
Sales Q2Q%79.12%
3.2 Future
The Earnings Per Share is expected to grow by 23.72% on average over the next years. This is a very strong growth
Based on estimates for the next years, OGI will show a quite strong growth in Revenue. The Revenue will grow by 9.53% on average per year.
EPS Next Y104.73%
EPS Next 2Y49.11%
EPS Next 3Y37.23%
EPS Next 5Y23.72%
Revenue Next Year22.53%
Revenue Next 2Y13.98%
Revenue Next 3Y10.71%
Revenue Next 5Y9.53%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
OGI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
OGI is valuated quite expensively with a Price/Forward Earnings ratio of 230.97.
OGI's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. OGI is cheaper than 67.19% of the companies in the same industry.
OGI's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 24.01.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 230.97 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates OGI does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as OGI's earnings are expected to grow with 37.23% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y49.11%
EPS Next 3Y37.23%
5. Dividend
5.1 Amount
No dividends for OGI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
1.92
-0.09 (-4.48%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners7.69%
Inst Owner Change19.76%
Ins Owners2.61%
Ins Owner ChangeN/A
Market Cap257.91M
Revenue(TTM)259.18M
Net Income(TTM)-24.76M
Analysts77.5
Price Target2.53 (31.77%)
Short Float %5.39%
Short Ratio8.05
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1338.94%
Min EPS beat(2)-2513.86%
Max EPS beat(2)-164.03%
EPS beat(4)1
Avg EPS beat(4)-540.26%
Min EPS beat(4)-2513.86%
Max EPS beat(4)916.83%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)5.78%
Min Revenue beat(2)3.01%
Max Revenue beat(2)8.56%
Revenue beat(4)3
Avg Revenue beat(4)1.34%
Min Revenue beat(4)-12.23%
Max Revenue beat(4)8.56%
Revenue beat(8)5
Avg Revenue beat(8)0.68%
Revenue beat(12)6
Avg Revenue beat(12)-1.21%
Revenue beat(16)9
Avg Revenue beat(16)0.34%
PT rev (1m)1.11%
PT rev (3m)-1.2%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 230.97 | ||
| P/S | 1.37 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.02 | ||
| P/tB | 1.43 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.18
EYN/A
EPS(NY)0.01
Fwd EY0.43%
FCF(TTM)-0.13
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS1.4
BVpS1.89
TBVpS1.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.4% | ||
| ROE | -7.09% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 6.64% | ||
| FCFM | N/A |
ROA(3y)-32.94%
ROA(5y)-24.98%
ROE(3y)-37.82%
ROE(5y)-28.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.46
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.22 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 94.85% | ||
| Cap/Sales | 6.58% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.26 | ||
| Quick Ratio | 1.28 | ||
| Altman-Z | -0.14 |
F-Score4
WACC8.35%
ROIC/WACCN/A
Cap/Depr(3y)85.08%
Cap/Depr(5y)98.16%
Cap/Sales(3y)9.58%
Cap/Sales(5y)15.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-258.7%
EPS Next Y104.73%
EPS Next 2Y49.11%
EPS Next 3Y37.23%
EPS Next 5Y23.72%
Revenue 1Y (TTM)62.15%
Revenue growth 3Y21.14%
Revenue growth 5Y24.46%
Sales Q2Q%79.12%
Revenue Next Year22.53%
Revenue Next 2Y13.98%
Revenue Next 3Y10.71%
Revenue Next 5Y9.53%
EBIT growth 1Y28.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year246.46%
EBIT Next 3Y66.74%
EBIT Next 5Y40.69%
FCF growth 1Y-1580.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-296.05%
OCF growth 3YN/A
OCF growth 5YN/A
ORGANIGRAM GLOBAL INC / OGI FAQ
Can you provide the ChartMill fundamental rating for ORGANIGRAM GLOBAL INC?
ChartMill assigns a fundamental rating of 3 / 10 to OGI.
What is the valuation status of ORGANIGRAM GLOBAL INC (OGI) stock?
ChartMill assigns a valuation rating of 1 / 10 to ORGANIGRAM GLOBAL INC (OGI). This can be considered as Overvalued.
What is the profitability of OGI stock?
ORGANIGRAM GLOBAL INC (OGI) has a profitability rating of 1 / 10.
What is the earnings growth outlook for ORGANIGRAM GLOBAL INC?
The Earnings per Share (EPS) of ORGANIGRAM GLOBAL INC (OGI) is expected to grow by 104.73% in the next year.